VA awards $33M for diagnostic test kits, raising questions about competition and value

Contract Overview

Contract Amount: $33,028,835 ($33.0M)

Contractor: Cepheid

Awarding Agency: Department of Veterans Affairs

Start Date: 2021-04-01

End Date: 2021-12-31

Contract Duration: 274 days

Daily Burn Rate: $120.5K/day

Competition Type: NOT COMPETED

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: CEPHEID GENEXPERT XPRESS TEST KITS

Place of Performance

Location: FREDERICK, FREDERICK County, MARYLAND, 21703

State: Maryland Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $33.0 million to CEPHEID for work described as: CEPHEID GENEXPERT XPRESS TEST KITS Key points: 1. Contract awarded on a sole-source basis, limiting potential for competitive pricing. 2. Significant award value for a single contractor, warranting scrutiny of cost-effectiveness. 3. Limited competition may indicate a lack of market alternatives or strategic sourcing. 4. Performance period of less than a year suggests a need for ongoing procurement. 5. Focus on diagnostic substance manufacturing highlights a critical healthcare supply chain component. 6. Awarded to a single manufacturer, potentially concentrating risk and limiting supply options.

Value Assessment

Rating: questionable

The contract value of $33 million for diagnostic test kits is substantial. Without competitive bidding, it is difficult to benchmark the pricing against market rates or similar contracts. The sole-source nature of this award raises concerns about whether the government secured the best possible value. Further analysis would be needed to compare the per-unit cost to industry standards for similar diagnostic kits.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded using a sole-source justification, meaning only one vendor, Cepheid, was solicited. This approach bypasses the standard competitive bidding process, which typically involves multiple vendors submitting proposals. While sole-source awards can be justified in specific circumstances (e.g., unique capabilities, urgent needs), they generally lead to less price discovery and potentially higher costs for the government.

Taxpayer Impact: Sole-source awards mean taxpayers may not benefit from the cost savings that can arise from a competitive bidding environment. The absence of competition can lead to higher prices than might be achieved if multiple companies vied for the contract.

Public Impact

Veterans will benefit from access to necessary diagnostic testing capabilities. The contract ensures the supply of In-Vitro Diagnostic Substance Manufacturing, crucial for medical diagnoses. Services are delivered to the Department of Veterans Affairs, supporting healthcare operations. The geographic impact is primarily within the VA healthcare system, serving veterans nationwide. Workforce implications include ensuring the availability of diagnostic tools for healthcare professionals.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Lack of competition may lead to inflated prices.
Sole-source award limits opportunities for other suppliers to enter the market.
Dependence on a single supplier could create supply chain vulnerabilities.
No clear indication of performance metrics or quality assurance in the provided data.

Positive Signals

Ensures critical diagnostic supplies are available to the VA.
Award supports a specific manufacturer in the diagnostic sector.
Contract addresses a clear need for In-Vitro Diagnostic Substance Manufacturing.

Sector Analysis

The market for In-Vitro Diagnostic Substance Manufacturing is a critical segment of the broader healthcare industry. This contract falls within the medical devices and diagnostics sector, which is characterized by innovation, regulatory oversight, and significant government procurement. Comparable spending benchmarks would typically involve analyzing other large-scale procurements of diagnostic kits by federal agencies or large healthcare systems.

Small Business Impact

The provided data indicates that this contract was not set aside for small businesses, nor is there information suggesting significant subcontracting opportunities for small businesses. The award to a single, likely larger, entity suggests that small businesses may not have been considered or were unable to meet the specific requirements of this sole-source procurement. This could limit their participation in supplying the VA with these critical diagnostic materials.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of Veterans Affairs' contracting and program management offices. Accountability measures would be defined in the contract's terms and conditions, including delivery schedules and product specifications. Transparency is limited due to the sole-source nature of the award, making public scrutiny of the procurement process more challenging. Inspector General jurisdiction would apply if any fraud, waste, or abuse were suspected.

Related Government Programs

Department of Veterans Affairs Medical Supplies
In-Vitro Diagnostic Devices
Federal Healthcare Procurement
Sole-Source Medical Contracts

Risk Flags

Sole-source award
Lack of competitive bidding
Potential for inflated pricing
Supply chain dependency

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $33.0 million to CEPHEID. CEPHEID GENEXPERT XPRESS TEST KITS

Who is the contractor on this award?

The obligated recipient is CEPHEID.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $33.0 million.

What is the period of performance?

Start: 2021-04-01. End: 2021-12-31.

What specific diagnostic tests are these kits intended for, and what is the clinical significance of these tests for veterans?

The provided data does not specify the exact diagnostic tests the Cepheid GeneXpert Xpress test kits are for. However, Cepheid's GeneXpert systems are known for rapid molecular diagnostics, capable of detecting a range of infectious diseases, including respiratory pathogens like influenza and COVID-19, as well as other conditions. For veterans, access to rapid and accurate diagnostic testing is crucial for timely treatment, disease management, and public health surveillance within VA facilities. The clinical significance lies in enabling healthcare providers to quickly identify illnesses, initiate appropriate treatment protocols, and prevent the spread of infections, thereby improving patient outcomes and operational efficiency within the VA healthcare system.

What was the justification for awarding this contract on a sole-source basis to Cepheid?

The justification for a sole-source award typically stems from unique capabilities, proprietary technology, or an urgent and compelling need where only one source can reasonably fulfill the requirement. For Cepheid's GeneXpert system, this could be due to the proprietary nature of their testing cartridges and the specific platform technology, which may not be compatible with other manufacturers' systems. Without the specific justification document, it's presumed that the VA determined Cepheid was the only responsible source capable of meeting the requirement within the necessary timeframe or technical specifications, potentially related to existing infrastructure or specific diagnostic needs that only Cepheid could address.

How does the $33 million award compare to historical spending on similar diagnostic test kits by the VA or other federal agencies?

The $33 million award represents a significant investment in diagnostic test kits. To provide a meaningful comparison, one would need to analyze historical contract data for similar types of molecular diagnostic kits, particularly those used on platforms like Cepheid's GeneXpert, across the Department of Veterans Affairs (VA) and other agencies like the Department of Defense or HHS. Factors such as the number of tests procured, the specific diseases targeted, and the contract duration would be essential for a fair comparison. Without access to detailed historical spending data and specific product comparisons, it's challenging to definitively state whether this award is high or low relative to past procurements. However, the sole-source nature suggests it might be at the higher end of what could be achieved through competition.

What are the potential risks associated with relying on a single supplier for critical diagnostic test kits?

Relying on a single supplier for critical diagnostic test kits, as is the case with this sole-source award to Cepheid, introduces several potential risks. Firstly, there's a risk of supply chain disruption; if Cepheid faces manufacturing issues, raw material shortages, or logistical problems, the VA's access to essential tests could be severely impacted, potentially affecting patient care. Secondly, the lack of competition can lead to higher prices over time, as the government has limited leverage to negotiate cost reductions. Thirdly, it can stifle innovation and prevent other capable small or large businesses from entering the market or offering alternative solutions. Finally, dependence on one vendor might limit the VA's ability to adopt newer, potentially more advanced or cost-effective technologies if they are not offered by Cepheid.

Are there any performance metrics or quality assurance clauses included in this contract that would ensure the effectiveness and reliability of the test kits?

The provided data snippet does not include details about specific performance metrics or quality assurance clauses within the contract. Typically, federal contracts for medical supplies would include specifications regarding product quality, efficacy, shelf-life, and delivery timelines. Performance would likely be monitored through adherence to these specifications and timely delivery. However, without the full contract details, it is impossible to assess the robustness of these measures or how they are enforced. The effectiveness and reliability of the test kits would be implicitly tied to meeting the manufacturer's stated performance standards and any specific requirements outlined by the VA.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › In-Vitro Diagnostic Substance Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Danaher Corporation

Address: 904 CARIBBEAN DR, SUNNYVALE, CA, 94089

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $61,878,385

Exercised Options: $33,028,835

Current Obligation: $33,028,835

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36C10X21D0015

IDV Type: IDC

Timeline